시장보고서

상품코드

1751299

심장 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 05월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심장 바이오마커 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 심장 바이오마커 시장은 2030년까지 511억 9,000만 달러에 달하며, 예측 기간 중 CAGR 14.1%로 확대할 것으로 예측됩니다.

급성관상동맥증후군(ACS)의 유병률 증가는 바이오마커 기술의 발전과 함께 시장 성장을 가속할 것으로 예측됩니다. 심장질환의 조기 진단 및 예후에 대한 인식이 높아지면서 시장을 더욱 견인할 것으로 예측됩니다.

클리블랜드 클리닉의 보고서에 따르면 미국에서는 1,800만 명 이상의 성인이 관상동맥성 심장질환을 앓고 있다고 합니다. 흉통은 응급실을 찾는 가장 흔한 이유 중 하나입니다. 심장병은 미국의 주요 사망 원인 중 하나이며, 41초마다 1명이 심장마비로 사망하는 것으로 추정됩니다. 심장 바이오마커는 ACS 진단에 중요한 역할을 하며, 보다 신속한 치료 방침을 결정할 수 있습니다.

급성관상동맥증후군의 위험도 계층화 및 진단을 위한 바이오마커의 채택이 증가하면서 수요가 증가하고 있습니다. 건강에 해로운 생활습관으로 인해 급성관상동맥증후군과 심근경색증의 유병률이 증가하고 있으며, PoC 진단의 채택이 증가하면서 심장 마커의 사용이 용이해져 부문 혁신이 촉진되고 있습니다. 병원과 PoC에서 심장 바이오마커를 사용하는 패러다임의 변화는 심근 트로포닌 I과 심근 트로포닌의 민감도에 대한 최근 분석법 개발 동향에 기인합니다.

심장 바이오마커 시장 보고서 하이라이트

유형별로는 트로포닌 부문이 심혈관 질환 진단에서 높은 사용률로 인해 2024년 35.5% 이상의 가장 큰 매출 점유율을 차지했습니다.
용도별로는 급성관상동맥증후군 분야가 2025-2030년 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
최종 용도에서는 실험실 검사 분야가 2024년 시장을 장악했습니다.
북미가 2024년 세계 시장을 독식하는 이유는 심장 바이오마커를 진단 및 예후 툴로 쉽게 채택할 수 있는 의료 시스템이 발달했기 때문입니다.
심장 바이오마커 시장에 참여하고 있는 주요 기업은 Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMERIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics 등입니다.
새로운 분석법의 가용성 증가는 향후 수년간 시장 성장을 가속할 것으로 예상되는 주요 요인 중 하나입니다. 예를 들어 2023년 10월 마인드 레이는 두 가지 고감도 심장 바이오마커 분석인 hs-cTnI 분석과 NT-proBNP 분석을 출시했습니다.

시장 계통 전망
- 모시장 전망
- 관련/부수 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
심장 바이오마커 시장 분석 툴
- 업계 분석 - Porter의 산업 분석
- PESTEL 분석
심장 바이오마커 시장 : 파이프라인 분석

제4장 심장 바이오마커 시장 : 유형별 추정·동향 분석

부문 대시보드
심장 바이오마커 시장 : 변동 분석
세계의 심장 바이오마커 시장 규모와 동향 분석(2018-2030년)
트로포닌
CK-MB
미오글로빈
불가역적 전기 천공 절제
BNP와 NT-PROBNP
기타

제5장 심장 바이오마커 시장 : 용도별 추정·동향 분석

부문 대시보드
심장 바이오마커 시장 : 변동 분석
세계의 심장 바이오마커 시장 규모와 동향 분석(2018-2030년)
급성 관상동맥 증후군
심근경색
울혈성심부전
기타

제6장 심장 바이오마커 시장 : 최종 용도별 추정·동향 분석

부문 대시보드
심장 바이오마커 시장 : 변동 분석
세계의 심장 바이오마커 시장 규모와 동향 분석(2018-2030년)
임상 검사
POC(Point of Care) 검사

제7장 심장 바이오마커 시장 : 지역 추정·동향 분석

지역 시장 대시보드
지역별 시장 점유율 분석, 2024년 및 2030년
지역별 시장 : 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
기업 개요
- Abbott
- Quidel Corporatio
- Siemens Healthcare Gmbh
- F. Hoffmann-La Roche Ltd.
- Danaher
- BIOMERIEUX
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
- Creative Diagnostics
- Life Diagnostics

KSA 25.06.27

Cardiac Biomarkers Market Growth & Trends:

The global cardiac biomarkers market is anticipated to reach USD 51.19 billion by 2030 and is anticipated to expand at a CAGR of 14.1% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.

Cardiac Biomarkers Market Report Highlights:

In terms of type, the troponin segment held the largest revenue share of over 35.5% in 2024 owing to its high usage in cardiovascular disease diagnosis
Based on application, the acute coronary syndrome segment is expected to grow at the fastest CAGR during 2025 - 2030
In terms of end use, laboratory testing segment dominated the market in 2024
North America dominated the global market in 2024 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
Key players operating in the cardiac biomarkers market include Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMERIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics
The rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. For instance, in October 2023, Mindray launched two highly sensitive cardiac biomarkers assays, hs-cTnI Assay, and NT-proBNP Assay, to diversify its portfolio in cardio biomarkers to provide enhanced cardiovascular disease care.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type
- 2.2.2. Application
- 2.2.3. End Use
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Cardiac Biomarkers Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market outlook
- 3.1.2. Related/ancillary Market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Cardiac Biomarkers Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
3.4. Cardiac Biomarkers Market : Pipeline Analysis

Chapter 4. Cardiac Biomarkers Market : Type Estimates & Trend Analysis

4.1. Type Segment Dashboard
4.2. Cardiac Biomarkers Market: Type Movement Analysis
4.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Troponin
- 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. CK-MB
- 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Myoglobin
- 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Irreversible Electroporation Ablation
- 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. BNP AND NT-PROBNP
- 4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Others
- 4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cardiac Biomarkers Market : Application Estimates & Trend Analysis

5.1. Application Segment Dashboard
5.2. Cardiac Biomarkers Market: Application Movement Analysis
5.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Acute Coronary Syndrome
- 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Myocardial Infarction
- 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Congestive Heart Failure
- 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
- 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cardiac Biomarkers Market: End Use Estimates & Trend Analysis

6.1. End Use Segment Dashboard
6.2. Cardiac Biomarkers Market: End Use Movement Analysis
6.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Laboratory Testing
- 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.5. Point of Care Testing
- 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cardiac Biomarkers Market : Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing Market by Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. U.S. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Canada Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. Mexico Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. UK
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. UK Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. Germany Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. France Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Italy Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. Spain Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.6. Norway
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Norway Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Regulatory framework/ reimbursement structure
  - 7.5.7.3. Competitive scenario
  - 7.5.7.4. Sweden Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.8. Denmark
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Regulatory framework/ reimbursement structure
  - 7.5.8.3. Competitive scenario
  - 7.5.8.4. Denmark Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Japan Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. China Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework/ reimbursement structure
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. India Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework/ reimbursement structure
  - 7.6.4.3. Competitive scenario
  - 7.6.4.4. Australia Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework/ reimbursement structure
  - 7.6.5.3. Competitive scenario
  - 7.6.5.4. South Korea Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.6. Thailand
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Regulatory framework/ reimbursement structure
  - 7.6.6.3. Competitive scenario
  - 7.6.6.4. Thailand Market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. Brazil Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Argentina Market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. MEA
- 7.8.1. South Africa
  - 7.8.1.1. Key country dynamics
  - 7.8.1.2. Regulatory framework/ reimbursement structure
  - 7.8.1.3. Competitive scenario
  - 7.8.1.4. South Africa Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework/ reimbursement structure
  - 7.8.2.3. Competitive scenario
  - 7.8.2.4. Saudi Arabia Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework/ reimbursement structure
  - 7.8.3.3. Competitive scenario
  - 7.8.3.4. UAE Market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Regulatory framework/ reimbursement structure
  - 7.8.4.3. Competitive scenario
  - 7.8.4.4. Kuwait Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
- 8.4.1. Abbott
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Quidel Corporatio
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. Siemens Healthcare Gmbh
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. F. Hoffmann-La Roche Ltd.
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. Danaher
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. BIOMERIEUX
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. Bio-Rad Laboratories, Inc.
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. Randox Laboratories Ltd.
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Creative Diagnostics
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. Life Diagnostics
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Product benchmarking
  - 8.4.10.4. Strategic initiatives